The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operational Update

13 Feb 2023 07:00

RNS Number : 6459P
MyCelx Technologies Corporation
13 February 2023
 

13 February 2023

 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Operational Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company transforming the environmental impact of industry, is pleased to provide an update on continued operational momentum, including the award and extension of contracts in the Middle East.

 

MYCELX has secured its second REGEN sale to another National Oil Company in the Middle East for water treatment during Enhanced Oil Recovery ("EOR") production. REGEN projects place MYCELX at the forefront of produced water treatment for EOR water and follow extensive technology evaluations where MYCELX successfully outperformed other available alternative technologies. As oil companies seek sustainable solutions for their aging production, REGEN allows producers to overcome the significant challenge that EOR produced water presents.

 

In addition to the sale mentioned above, the Company continues to generate momentum in Saudi Arabia with the conversion of an emergency response project into a longer-term deployment and a new project win to treat some of the most contaminated industrial wastewater in the country.

 

These latest project wins are noteworthy because they possess a shorter cash conversion cycle and longer project durations which ensure cash flows to support MYCELX's working capital requirements. These projects are expected to, in aggregate, contribute $2.3 million in revenue this year, underpinning the 2023 revenue forecast. The Company remains on track to meet its current financial guidance for 2023 with cash flows anticipated to remain stable throughout the year.

 

Connie Mixon, CEO, commented:

 

"We are very pleased to be announcing today's Operating Update, which demonstrates the continued commercial advancements we are making as a business. Our pipeline of opportunities has returned to pre pandemic levels with higher quality and more diversity across our three operating segments. We look forward to updating the market on the Company's progress throughout the year."

 

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRBIGDDGUBDGXB
Date   Source Headline
3rd Jun 20133:19 pmRNSTotal Voting Rights
28th May 20135:02 pmRNSHolding(s) in Company
28th May 20132:54 pmRNSDirector/PDMR Shareholding
24th May 20138:52 amRNSHolding(s) in Company
14th May 20132:14 pmRNSResult of Annual Meeting
14th May 20137:00 amRNSOperational Update & Directorate Change
9th May 20137:00 amRNSExercise of Warrant
23rd Apr 201312:49 pmRNSApplication for Block Admission
19th Apr 20137:00 amRNSAnnual Financial Report/Directorate Change
15th Apr 20132:18 pmRNSHolding(s) in Company
26th Mar 20135:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.